AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2021
Jan 5, 2021
29821_dirs_2021-01-05_3f4e5f6b-9c40-48b6-9258-2acde22abdcc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2021-01-01
Reporting Person: Fitzgerald Joseph Michael (EVP & Pres, Interven Cardio)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-01 | Common Stock | M | 27199.0000 | $0.0000 | Acquired | 248247.0000 | Direct |
| 2021-01-01 | Common Stock | F | 13619.0000 | $35.9500 | Disposed | 234628.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-01 | Performance Share Units | $ | M | 27199.0000 | Disposed | 2020-12-31 | Common Stock (27199.0000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 68329.0000 | Indirect |
| Common Stock | 6777.0000 | Indirect |
Footnotes
F1: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020.
F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3: The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
F4: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.